Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LeonaBio, Inc. (LONA : NSDQ)

• Company Description    LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $7.39 Daily Weekly Monthly 20 Day Moving Average: 41,772 shares Shares Outstanding: 9.39 (millions) Market Capitalization: $69.42 (millions) Beta: 2.01 52 Week High: $14.21 52 Week Low: $3.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.96% -15.58% 12 Week -18.79% -21.02% Year To Date -2.38% -11.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18706 North Creek Parkway Suite 104 - Bothell,WA 98011 USA ph: 425-620-8501 fax: - ir@athira.com https://leonabio.com

• General Corporate Information    Officers Mark Litton - President; Chief Executive Officer and Director Kelly A. Romano - Chairwoman of the Board of Directors Robert Renninger - Chief Financial Officer Joseph Edelman - Director James A. Johnson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04746L203 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 9.39 Most Recent Split Date: 9.00 (0.10:1) Beta: 2.01 Market Capitalization: $69.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 24.78% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -381.01 12/31/25 - -340.97 ROA 06/30/26 - - 03/31/26 - -225.74 12/31/25 - -209.91 Current Ratio 06/30/26 - - 03/31/26 - 10.38 12/31/25 - 1.88 Quick Ratio 06/30/26 - - 03/31/26 - 10.38 12/31/25 - 1.88 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 5.25 12/31/25 - 2.98 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©